AbCellera Biologics Inc. (FRA:8QQ)

Market Cap	1.12B
Revenue (ttm)	30.11M
Net Income (ttm)	-146.32M
Shares Out	n/a
EPS (ttm)	-0.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,850
Average Volume	1,495
Open	3.455
Previous Close	3.696
Day's Range	3.455 - 3.672
52-Week Range	1.701 - 5.780
Beta	n/a
RSI	64.05
Earnings Date	Feb 20, 2026

About AbCellera Biologics

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 596
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8QQ

Financial Performance

In 2024, AbCellera Biologics's revenue was $28.83 million, a decrease of -24.17% compared to the previous year's $38.03 million. Losses were -$162.86 million, 11.2% more than in 2023.

Financial numbers in USD